FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study

Takeda Pharmaceutical Co Ltd TAK received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral suspension) for eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.

  • The CRL indicates the FDA has completed its review of the TAK-721 NDA and determined that it cannot be approved in its present form. 
  • Related content: Benzinga's Full FDA Calendar.
  • In addition, the FDA recommended an additional clinical study to help resolve FDA feedback. 
  • “Takeda is assessing the details of the CRL and evaluating a regulatory path forward,” said Ramona Sequeira, President, U.S. Business Unit, and Global Portfolio Commercialization.
  • TAK-721 (budesonide oral suspension) is an oral viscous formulation of budesonide. It entered the Takeda pipeline through the company’s acquisition of Shire.
  • Price Action: TAK shares are closed at $13.75 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!